Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study (Breast Cancer Research, (2017), 19, 1, (130), 10.1186/s13058-017-0920-8)

Following publication of the original article [1], the authors would like to correct several typos in the article text: 1) Page 4-right panel, Line 10: “The take rate was 51.3% (21/39; 95% CI: 34.8-67.6%) in TN subtype;”. Take rate should be 20/39 not 21/39. Percentages are correct. 2) Page 4-right panel, Line 21: The last 2 sentences were corrected to be consistent with Table 2 as follows: “There was no take among the 18 luminal tumors. However, five of nine TN, and one of the eight HER2+ post-chemotherapy residual tumors took (verified breast tumor).” 3) Page 4-right panel, Table 2: Total implanted for Luminal B should be 14 instead of 18. The total number of implanted 35 was correct. 4) Page 5-left panel, Line 15: HER2+ tumors (7/17 vs. 2/15) should be (7/19 vs. 2/15). P-value is correct. 5) Page 5-left panel, Line 20, The number of luminal tumors should be 18 instead of 22. The authors sincerely apologize for any inconvenience.